Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy.
Cutaneous Biology Research Center, Massachusetts General Hospital, Boston.
Jennifer A
JA
Lo
Cutaneous Biology Research Center, Massachusetts General Hospital, Boston2Department of Dermatology, Massachusetts General Hospital, Boston3Massachusetts General Hospital Cancer Center, Boston.
David E
DE
Fisher
Massachusetts General Hospital Cancer Center, Boston.
Keith T
KT
Flaherty
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D004334:Drug Administration Schedule; D003875:Drug Eruptions / Q000209:etiology*; D006801:Humans; D017496:Hypopigmentation / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D011537:Pruritus / Q000139:chemically induced; D012189:Retrospective Studies; D017444:Skin Diseases, Papulosquamous / Q000139:chemically induced; D016896:Treatment Outcome
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C582435:pembrolizumab